Peptide

Thymosin Beta-4

Also known as

Tβ4 · TB4 · TB-4 · Thymosin β4 · Timbetasin (INN) · full-sequence TB4 · full-length thymosin beta-4 · RGN-259 (0.1% ophthalmic research formulation) · TMSB4X gene product (endogenous context) · synthetic Tβ4 (clinical IV / wound-gel programs)

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Full-length TB4	A naturally occurring 43-amino-acid peptide involved in actin regulation and cell movement. People discuss it for injury recovery and easier movement; that role does not prove tendon repair.
TB-500 identity varies	Community labels can mean full TB4 or a shorter fragment. The FDA fragment entry names LKKTETQ; these identities are not interchangeable.

Notes

Thymosin Beta-4, or TB4, is a peptide naturally present in the body that people discuss for injury recovery, stiffness and easier movement. Full-length TB4 and products called TB-500 are often mixed together in those discussions. Reports include improvement, no change and unwanted fatigue; a recovery story does not establish what was in the product or prove tissue healing.

Full TB4 contains 43 amino acids. It helps regulate actin, part of the machinery cells use to move. That biological role underlies the repair narrative; it does not prove that an injectable product repairs a human tendon. Xiong et al. — TB4 treatment six hours after traumatic brain injury in rats (2012) (Animal context · Accessed 2026-09-30)

TB-500 is an unreliable shorthand for identity. Forum users describe both full TB4 and the shorter 17–23 fragment under this name. FDA's fragment entry specifically identifies LKKTETQ. A familiar label cannot make the full peptide and fragment interchangeable. Difference between TB4 and TB500 & Dosing Recommendation (Community discussion · Accessed 2026-09-30) · FDA — compounding substances that may present significant safety risks (Official context · Accessed 2026-09-30)

Source context — Xiong et al. — TB4 treatment six hours after traumatic brain injury in rats (2012): PMC HTML challenge; actual text inspected through NCBI BioC API. Human PK values are a secondary quotation within a rat paper, not animal half-lives or a fresh primary human measurement. No animal dose transferred to community fields. Below 75 source-derived article words.

Source context — Difference between TB4 and TB500 & Dosing Recommendation: Secondhand molecular and PK assertions mixed with questions and seller mentions. No sequence testing or comparison trial. Seller links, mixing speculation and directives excluded.

Source context — FDA — compounding substances that may present significant safety risks: Specifically a fragment compounding-risk entry, not a full-TB4 trial or universal legal classification. No personalized risk recommendation.

What people notice

Less stiffness or easier movement	Favorable accounts often include BPC-157, rehabilitation and reduced training. One user reported an improved elbow while their shoulder also received cortisone.
No change or fatigue	A BPC/TB blend user reported no improvement at day twenty. Another commenter described lethargy into the next day after 500 mcg TB4 in the evening.

Notes

Less stiffness and easier movement. The community appeal is returning to daily activity or training after strains, tendon irritation and overuse. Accounts often include BPC-157, physical therapy, less training and better sleep, making TB4's contribution hard to separate.

Improvement can differ between injuries. One person reported a good elbow outcome while the shoulder received cortisone. Other users reported no improvement with a BPC/TB blend. Neither account establishes a predictable repair response. TB-500 THYMOSIN BETA 4 Dosage (Personal report · Accessed 2026-09-30) · What to do if not seeing results from Bpc157 and tb500? (Personal report · Accessed 2026-09-30)

No improvement can persist despite a stack. The day-20 blend report described 500 mcg each of BPC/TB daily with no change in two injuries. Replies disagreed about identity and schedule; suggestions to raise amounts or change vendors do not prove why it failed. What to do if not seeing results from Bpc157 and tb500? (Personal report · Accessed 2026-09-30)

Unwanted lethargy lasted into the next day in one report. A commenter described this after 500 mcg TB4 in the evening. Feeling an effect the next day does not measure the peptide's blood half-life or establish how long a benefit lasts. Thymosin Beta-4, daily dosing or bi weekly? (Community discussion · Accessed 2026-09-30)

Source context — TB-500 THYMOSIN BETA 4 Dosage: Unverified full peptide versus fragment; two injuries, BPC and cortisone confound attribution. Dose conversion retained as peptide mass, without vial-volume or syringe instructions. Duplicated start comment is one report.

Source context — What to do if not seeing results from Bpc157 and tb500?: Product identity and actual delivered amount unverified. No response at day 20 is not permanent failure. Replies prescribing escalation, vendors and unsupported fragment superiority not adopted.

Source context — Thymosin Beta-4, daily dosing or bi weekly?: BPC co-use in OP; proposals are not completed protocols. Product identity and symptoms unverified. The 1.8–2.1-hour figure is formal-study repetition; linked figure not independently inspected. No SubQ PK measurement.

Doses people talk about

Daily SubQ: 0.5–1 mg	This band appears in full-TB4 charts. One opened account began 0.75 mg daily with BPC, without verified product identity.
Twice-weekly: 2–2.5 mg each	The TB-500-style SubQ chart totals 4–5 mg/week. Higher charts separately list 2.5–5 mg twice weekly; these are not measured dose comparisons.
Weekly chart totals	Other loading summaries list 5–10 mg/week and maintenance 1–5 mg/week. These weekly totals are different from a daily amount or a vial's total contents.

Notes

Daily SubQ: 0.5–1 mg in full-TB4 discussion. Existing charts describe 500–1,000 mcg daily. One opened account began 0.75 mg daily with BPC; another thread discussed 500–750 mcg daily versus 2–2.5 mg twice weekly. Product identity remained unverified. TB-500 THYMOSIN BETA 4 Dosage (Personal report · Accessed 2026-09-30) · Thymosin Beta-4, daily dosing or bi weekly? (Community discussion · Accessed 2026-09-30)

Twice-weekly SubQ: 2–2.5 mg per administration. The existing TB-500-style chart applied to claimed full TB4 totals 4–5 mg/week. Higher charts separately list 2.5–5 mg twice weekly, including 5 mg twice weekly for two weeks before reducing. Those are chart claims, not measured dose comparisons.

Weekly loading totals: 5–10 mg in existing full-TB4 talk. Other preserved summaries span 4–10 mg/week and maintenance 1–5 mg/week. Clinic/secondary writeups separately describe SubQ 3–5 times weekly without a fixed amount, or 2–5 mg twice weekly with daily BPC for eight weeks.

Wolverine, GLOW and KLOW amounts are component amounts. Existing vial examples list BPC/TB 5/10 mg (1:2); GHK-Cu/BPC/TB 50/10/10 mg (5:1:1), with 27/5/10 also recorded; and GHK-Cu/BPC/TB/KPV 50/10/10/10 mg. These are vial totals, not daily doses. An old GLOW estimate of about 0.3 mg TB/day depends on an unspecified draw.

Half-life, onset & duration

Felt onset	One TB-500 log described less chest tightness after a week; a separate blend user had no improvement at day twenty. Neither establishes a full-TB4 response window.
Felt duration	Some accounts describe mobility changes days to weeks after stopping alongside rehabilitation. No dependable single-dose benefit duration is established.
Half-life	Secondary reporting gives human IV TB4 means of 0.95–2.1 hours across different study amounts. This does not establish SubQ kinetics for injury products.
TB-500 timing claims	Unmeasured claims of 2–4 days or 7–10 days conflict in the saved discussions. They cannot establish full-TB4 clearance or a multi-day depot.

Notes

One week in one TB-500 log; no improvement at day 20 in a blend account. The log described less chest tightness after a week; the blend user still had foot and wrist symptoms. Neither product was sequence-verified, so these are contrasting experiences rather than a full-TB4 onset window. TB 500 log (Personal report · Accessed 2026-09-30) · What to do if not seeing results from Bpc157 and tb500? (Personal report · Accessed 2026-09-30)

No dependable single-dose benefit duration. Existing accounts say mobility changes sometimes continue days to weeks after stopping, alongside rehabilitation. The elbow follow-up reports a later outcome without an offset time. A weeks-long course is not one dose's duration. TB-500 THYMOSIN BETA 4 Dosage (Personal report · Accessed 2026-09-30)

IV plasma half-lives: 0.95, 1.2, 1.9 and 2.1 hours. A later rat paper quotes these human means for 42, 140, 420 and 1,260 mg, respectively. This is secondary reporting of human IV measurements, not SubQ kinetics. Xiong et al. — TB4 treatment six hours after traumatic brain injury in rats (2012) (Animal context · Accessed 2026-09-30)

TB-500 claims conflict: 2–4 days or 7–10 days. Separate Reddit threads repeat these estimates without a matching human clearance measurement. They cannot establish full-TB4 half-life. The claim that repair signaling lasts longer than blood exposure also does not establish a multi-day depot. Difference between TB4 and TB500 & Dosing Recommendation (Community discussion · Accessed 2026-09-30) · Thymosin Beta 4 & TB500 are termed interchangeably, but both have different half-lives? (Secondhand community claim · Accessed 2026-09-30)

Source context — TB 500 log: Only page 1 inspected; full TB4 versus fragment unresolved. Training changes and other treatments uncontrolled. Procurement and worst-case-only-money reassurance excluded. Article uses less than 75 derived words from this source.

Source context — Thymosin Beta 4 & TB500 are termed interchangeably, but both have different half-lives?: Evidence that these estimates circulate, not a measurement or consensus. Linked vendor and Google document not inspected or adopted.

Cycles people discuss

Competing loading patterns	Existing notes describe about two weeks daily or four–six weeks twice weekly, followed by stopping or lower-frequency maintenance.
Injury blocks	Four–eight-week blocks appear, with six–eight-week clinic summaries and eight–twelve-week chronic-use talk. One TB-500 account used 5 mg weekly for a couple of months.
Breaks remain disputed	Charts include weeks off, seasonal breaks or one month off per three months on. None establishes a safe continuous course or necessary reset.

Notes

Loading: about 2 weeks daily, or 4–6 weeks twice weekly. These are competing patterns in existing notes, followed by stopping or lower-frequency maintenance. Daily and twice-weekly charts do not establish equivalent exposure.

Injury blocks: 4–8 weeks; longer accounts also exist. Existing clinic summaries mention 6–8 weeks and chronic-use talk 8–12 weeks. Maintenance includes once weekly, twice-weekly lower doses or stopping, without agreement.

A couple of months in one TB-500 account. An AnabolicMinds user reported 5 mg weekly; replies disputed course length. Full-TB4 identity was unresolved. BPC 157, formerly written by me! For all injured athletes! (Community discussion · Accessed 2026-09-30)

Break schedules are claims, not established safety rules. Existing examples include weeks off after 6–8 weeks on, seasonal breaks, or one month off per three months on. Blend blogs describe 30 days on/at least 15 off or 4–12-week courses. None demonstrates safe continuous use or a necessary reset.

Source context — BPC 157, formerly written by me! For all injured athletes!: Unverified TB-500 identity and highly confident bro-science guidance. Unsupported year-round safety, healing guarantees and procurement not adopted. Less than 75 source-derived article words allocated to this shared URL.

Stacks

Wolverine: BPC plus TB	BPC-157 pairings include 250–500 mcg/day, or separate 200–500 mcg per-use reports once or twice daily. TB labels and daily versus intermittent schedules differ.
GLOW and KLOW	GLOW adds GHK-Cu; KLOW adds KPV too. Example 50/10/10 and 50/10/10/10 mg compositions are vial totals, not daily amounts.
Further additions	Some combine TB with GHK-Cu separately, GH-axis compounds or other immune-focused peptides. Rehabilitation, deload and sleep also accompany results; these combinations do not establish synergy.

Notes

BPC co-use can dominate the story. Existing Wolverine talk includes BPC 250–500 mcg/day, or 200–500 mcg per administration once or twice daily, alongside TB. GHK-Cu, KPV and GH-axis additions bring further confounding. Physical therapy, deload and sleep are repeatedly credited too; a stack is not proven synergy.

Wolverine stack (dominant): Full TB4 or TB-500 + BPC-157 — top injury dual stack; labels blur between full molecule and fragment. Typical talk: BPC ~250–500 mcg daily + TB multi-mg 1–2×/week (or full-TB4 daily low-mg chart). [community]

GLOW stack: TB4/TB-500 + BPC-157 + GHK-Cu for skin + recovery crossover; common vendor vial talk 50/10/10 mg GHK/BPC/TB (ratios vary). [community]

KLOW stack: GLOW + KPV for added anti-inflammatory narrative; common talk ~50/10/10/10 mg class totals — vendor-variable. [community]

GH-axis add-ons: Sometimes stacked with CJC-1295 / Ipamorelin or other secretagogues for “recovery + GH” blocks — multi-agent confounded logs. [community]

TB4 + GHK-Cu (without full GLOW branding): Repair + collagen/skin remodeling talk; GHK often charted separately (e.g. low-mg multi-weekly) when not in a pre-mix. [community]

Inflammation extras: Occasional KPV, thymosin alpha-1, or LL-37 adjacency in advanced forums — different risk profiles. [community]

PT / deload / sleep: Physical therapy, load management and sleep are repeatedly credited with improvement alongside peptide use. Their contribution makes the peptide's effect difficult to isolate. [community]

What stacks are not: Not proven synergistic RCTs; more mg and more agents increase cost, identity risk, and confound interpretation. [community] [trial]

Watch for

Reported reactions	Sting, redness, swelling, fatigue, headache and flu-like feelings appear. Their frequency is unknown, and contents or purity are not verified by a label.
Fragment warning	FDA flags immune-reaction and impurity concerns for LKKTETQ, with no human exposure data in that entry. This is a fragment warning, not a full-TB4 trial result.
Cancer and long-term unknowns	Cancer-related cell-growth concerns remain unresolved. Pregnancy, childhood and medicine combinations also lack an established injury-use safety picture.
Sport rules	The saved WADA context prohibits thymosin-β4 and derivatives such as TB-500 at all times.

Notes

Irritation, fatigue and headache are reported. Existing notes include sting, redness, swelling, lethargy and flu-like feelings. Their frequency is unknown. Mislabeling, contamination and inaccurate content remain concerns; a label or testimonial does not verify a product. Thymosin Beta-4, daily dosing or bi weekly? (Community discussion · Accessed 2026-09-30)

The fragment has a separate safety warning. FDA flags possible immune reactions from aggregation and impurities for LKKTETQ and says it lacks human exposure data. This fragment warning must not be described as a full-TB4 trial result. FDA — compounding substances that may present significant safety risks (Official context · Accessed 2026-09-30)

Cancer concerns remain unresolved. Community cautions connect blood-vessel growth and cell migration with active or recent cancer. They do not establish that injury-use TB4 causes cancer, or that such use is safe. Pregnancy, pediatric use and interactions with other medicines also lack an established injury-use safety picture.

Thymosin-β4 and TB-500 are prohibited in WADA sport. The prohibited list names thymosin-β4 and its derivatives under S2.3, at all times. Recovery intent does not remove that sport-rule issue. WADA — Prohibited List, S2.3 (Official context · Accessed 2026-09-30)

Source context — WADA — Prohibited List, S2.3: Sport-rule context only; not criminal legal status, clearance, testing or evasion guidance.

Full notes

What TB4 is

Full TB4 contains 43 amino acids. It helps regulate actin, part of the machinery cells use to move. That biological role underlies the repair narrative; it does not prove that an injectable product repairs a human tendon. Animal context
TB-500 is an unreliable shorthand for identity. Forum users describe both full TB4 and the shorter 17–23 fragment under this name. FDA's fragment entry specifically identifies LKKTETQ. A familiar label cannot make the full peptide and fragment interchangeable. Reddit · r/Peptides Official context
SubQ is the main route in the existing injury discussions. SubQ means beneath the skin; abdomen versus near-injury placement is debated. IM muscle injections appear too. These reports do not establish an advantage for placement near an injury. Community

Benefits people seek

Less stiffness and easier movement. The community appeal is returning to daily activity or training after strains, tendon irritation and overuse. Accounts often include BPC-157, physical therapy, less training and better sleep, making TB4's contribution hard to separate. Community Community
Improvement can differ between injuries. One person reported a good elbow outcome while the shoulder received cortisone. Other users reported no improvement with a BPC/TB blend. Neither account establishes a predictable repair response. Personal report Personal report

Doses people discuss

Reported amounts, not instructions. 1 mg equals 1,000 mcg. The figures below describe different products and schedules; they are not one validated range.

Daily SubQ: 0.5–1 mg in full-TB4 discussion. Existing charts describe 500–1,000 mcg daily. One opened account began 0.75 mg daily with BPC; another thread discussed 500–750 mcg daily versus 2–2.5 mg twice weekly. Product identity remained unverified. Community Personal report Reddit · r/Peptides
Twice-weekly SubQ: 2–2.5 mg per administration. The existing TB-500-style chart applied to claimed full TB4 totals 4–5 mg/week. Higher charts separately list 2.5–5 mg twice weekly, including 5 mg twice weekly for two weeks before reducing. Those are chart claims, not measured dose comparisons. Community
Weekly loading totals: 5–10 mg in existing full-TB4 talk. Other preserved summaries span 4–10 mg/week and maintenance 1–5 mg/week. Clinic/secondary writeups separately describe SubQ 3–5 times weekly without a fixed amount, or 2–5 mg twice weekly with daily BPC for eight weeks. Community
Wolverine, GLOW and KLOW amounts are component amounts. Existing vial examples list BPC/TB 5/10 mg (1:2); GHK-Cu/BPC/TB 50/10/10 mg (5:1:1), with 27/5/10 also recorded; and GHK-Cu/BPC/TB/KPV 50/10/10/10 mg. These are vial totals, not daily doses. An old GLOW estimate of about 0.3 mg TB/day depends on an unspecified draw. Community

Half-life

About 2 hours is repeated for full TB4. A daily-dosing thread cites 1.8–2.1 hours from human Phase I research via a ResearchGate figure. That is a formal-study claim repeated by a user, not measured SubQ kinetics for their product. Reddit · r/Peptides
TB-500 claims conflict: 2–4 days or 7–10 days. Separate Reddit threads repeat these estimates without a matching human clearance measurement. They cannot establish full-TB4 half-life. The claim that repair signaling lasts longer than blood exposure also does not establish a multi-day depot. Reddit · r/Peptides Reddit · r/Peptides Community

Onset: when people notice a change

One week in one TB-500 log; no improvement at day 20 in a blend account. The log described less chest tightness after a week; the blend user still had foot and wrist symptoms. Neither product was sequence-verified, so these are contrasting experiences rather than a full-TB4 onset window. Personal report Personal report
Existing notes describe changes over weeks 1–4. They distinguish early stiffness changes, mobility shifts around weeks 2–3 and reassessment around weeks 3–4. Rehab and reduced load overlap; a later improvement cannot identify the peptide's onset. Community

Duration: how long changes last

No dependable single-dose benefit duration. Existing accounts say mobility changes sometimes continue days to weeks after stopping, alongside rehabilitation. The elbow follow-up reports a later outcome without an offset time. A weeks-long course is not one dose's duration. Community Personal report
Unwanted lethargy lasted into the next day in one report. A commenter described this after 500 mcg TB4 in the evening. Feeling an effect the next day does not measure the peptide's blood half-life or establish how long a benefit lasts. Reddit · r/Peptides

Cycles and time off

Loading: about 2 weeks daily, or 4–6 weeks twice weekly. These are competing patterns in existing notes, followed by stopping or lower-frequency maintenance. Daily and twice-weekly charts do not establish equivalent exposure. Community
Injury blocks: 4–8 weeks; longer accounts also exist. Existing clinic summaries mention 6–8 weeks and chronic-use talk 8–12 weeks. Maintenance includes once weekly, twice-weekly lower doses or stopping, without agreement. Community
A couple of months in one TB-500 account. An AnabolicMinds user reported 5 mg weekly; replies disputed course length. Full-TB4 identity was unresolved. AnabolicMinds
Break schedules are claims, not established safety rules. Existing examples include weeks off after 6–8 weeks on, seasonal breaks, or one month off per three months on. Blend blogs describe 30 days on/at least 15 off or 4–12-week courses. None demonstrates safe continuous use or a necessary reset. Community

Watch for

Irritation, fatigue and headache are reported. Existing notes include sting, redness, swelling, lethargy and flu-like feelings. Their frequency is unknown. Mislabeling, contamination and inaccurate content remain concerns; a label or testimonial does not verify a product. Community Reddit · r/Peptides
The fragment has a separate safety warning. FDA flags possible immune reactions from aggregation and impurities for LKKTETQ and says it lacks human exposure data. This fragment warning must not be described as a full-TB4 trial result. Official context
Cancer concerns remain unresolved. Community cautions connect blood-vessel growth and cell migration with active or recent cancer. They do not establish that injury-use TB4 causes cancer, or that such use is safe. Pregnancy, pediatric use and interactions with other medicines also lack an established injury-use safety picture. Community
Thymosin-β4 and TB-500 are prohibited in WADA sport. The prohibited list names thymosin-β4 and its derivatives under S2.3, at all times. Recovery intent does not remove that sport-rule issue. Official context

What the community experiences add

No improvement can persist despite a stack. The day-20 blend report described 500 mcg each of BPC/TB daily with no change in two injuries. Replies disagreed about identity and schedule; suggestions to raise amounts or change vendors do not prove why it failed. Personal report
Solo TB and combined results can differ. An AnabolicMinds user noticed little from solo TB-500 and credited BPC more strongly. Another favored TB for muscles and tendons over joints. These disagreements are useful, but neither account verifies full-TB4 identity or comparative effectiveness. AnabolicMinds
BPC co-use can dominate the story. Existing Wolverine talk includes BPC 250–500 mcg/day, or 200–500 mcg per administration once or twice daily, alongside TB. GHK-Cu, KPV and GH-axis additions bring further confounding. Physical therapy, deload and sleep are repeatedly credited too; a stack is not proven synergy. Community Community
Schedule convenience and timing preferences affect reports. One poster preferred twice-weekly TB to reduce injection frequency while describing daily BPC. Existing notes contain morning/evening and training/rest-day preferences without controlled comparisons. These practical differences help explain competing schedules, without deciding which works better. Reddit · r/Peptides Community
Skin and hair claims are a smaller branch of discussion. Existing notes retain occasional skin or hair anecdotes and claims that full TB4 is more complete than a fragment. Those claims draw on biological theory and other formulations; they do not establish superiority for sports injuries. Community

What formal research adds

Human IV research used 42, 140, 420 or 1,260 mg. Ruff's study involved 40 healthy volunteers, single dosing and 14 days of daily dosing, with no serious adverse events reported. Short-term IV findings do not establish SubQ injury-product effectiveness or long-term safety. Official context
IV plasma half-lives: 0.95, 1.2, 1.9 and 2.1 hours. A later rat paper quotes these human means for 42, 140, 420 and 1,260 mg, respectively. This is secondary reporting of human IV measurements, not SubQ kinetics. Animal context
Wound gels and 0.1% eye drops have their own programs. The venous-ulcer registry lists 0.01%, 0.03% and 0.1% gel daily for up to 84 days. A small RGN-259 eye trial showed a healing trend but missed statistical significance for its primary endpoint. Neither supplies an injectable sports-recovery dose or outcome promise. Official context Official context